SEC Comment Letter for Hoth Therapeutics, Inc. (HOTH) (CIK 0001711786) (RKTO) — Apr 17, 2024
Hoth Therapeutics, Inc. (HOTH) (CIK 0001711786)
Date: April 17, 2024 · CIK: 0001711786 · Accession: 0000000000-24-004181
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278620
Letter
United States securities and exchange commission logo April 17, 2024 Robb Knie Chief Executive Officer Hoth Therapeutics, Inc. 590 Madison Ave., 21st Floor New York, NY 10022 Re:Hoth Therapeutics, Inc. Registration Statement on Form S-1 Filed April 11, 2024 File No. 333-278620 Dear Robb Knie: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Chris Edwards at 202-551-6761 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Emily A. Mastoloni, Esq.
Show Raw Text
United States securities and exchange commission logo
April 17, 2024
Robb Knie
Chief Executive Officer
Hoth Therapeutics, Inc.
590 Madison Ave., 21st Floor
New York, NY 10022
Re:Hoth Therapeutics, Inc.
Registration Statement on Form S-1
Filed April 11, 2024
File No. 333-278620
Dear Robb Knie:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Chris Edwards at 202-551-6761 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Emily A. Mastoloni, Esq.